Clinical Trial: NCT04549207
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 4| Lead Sponsor: | Ottawa Hospital Research Institute |
| Information Provided By: | Ottawa Hospital Research Institute |
| Last Update Posted: | 2026-07-21 |
Study Overview
Brief Summary
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
Official Title
A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)
Conditions
Breast Cancer, Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Bone modifying agent
Other Study ID Numbers
- REaCT-Hold BMA
Start Date (Actual)
2020-10-09
Primary Completion Date (Actual)
2025-04-17
Study Completion Date (Estimated)
2026-09
Enrollment (Actual)
240
Study Type
Interventional
Phase
Phase 4
| Lead Sponsor: | Ottawa Hospital Research Institute |
| Information Provided By: | Ottawa Hospital Research Institute |
| Last Update Posted: | 2026-07-21 |
Study Overview
Brief Summary
The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
Official Title
A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)
Conditions
Breast Cancer, Castration-resistant Prostate Cancer
Intervention / Treatment
- Drug: Bone modifying agent
Other Study ID Numbers
- REaCT-Hold BMA
Start Date (Actual)
2020-10-09
Primary Completion Date (Actual)
2025-04-17
Study Completion Date (Estimated)
2026-09
Enrollment (Actual)
240
Study Type
Interventional
Phase
Phase 4